Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Baumert, Brigitta G, Hegi, Monika E, van den Bent, Martin J · The Lancet Oncology · 2016